Healthcare Apr 25, 2022 06:13 PM (GMT+8) · EqualOcean
Yiouda health on April 26, Baiyang Pharmaceutical (301015. SZ), a third-party health brand commercialization platform, released its 2021 annual report, which is the first annual report of the company after its listing. According to the annual report, Baiyang pharmaceutical achieved an annual operating revenue of 7.052 billion yuan, a year-on-year increase of 19.94%; The net profit attributable to the shareholders of the listed company was 423 million yuan, a year-on-year increase of 55.04%; The dividend reaches 38% of the distributable profit. According to the data of the first quarterly report of 2022 disclosed on the same day, the operating revenue of Baiyang pharmaceutical in the first quarter of 2022 was 1.86 billion yuan, a year-on-year increase of 14.43%; The net profit attributable to shareholders of listed companies was 88 million yuan, a year-on-year increase of 2.79%. During the reporting period, the growth rate of many banner products such as Diqiao series, MIT series and hale series increased steadily, realizing operating revenue of 1.378 billion yuan, 310 million yuan and 360 million yuan respectively, with a year-on-year increase of 16.41%, 12.02% and 22.95%. It is particularly noteworthy that the newly added operating brand Hailu series achieved an operating revenue of 298 million yuan.

This text is a result of machine translation.